SCHEMBL29763230

SCHEMBL29763230

CC(C)Nc1nc(Nc2cccc(S(C)(=O)=O)c2)nc(-c2c(F)cccc2F)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK9 P50750 2/20 0.47
▸ CCNT1 O60563 1/20 0.47
▸ CCNE1 P24864 1/20 0.47
▸ CDK2 P24941 1/20 0.47
▸ IDH1 O75874 2/20 0.47
▸ IDH2 P48735 1/20 0.47
▸ KCNH3 Q9ULD8 8/20 0.46
▸ POLB P06746 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ SYK P43405 1/20 0.42
▸ ROCK1 Q13464 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ LCK P06239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15102531 1.00 CDK9 (0.47) CDK9CCNT1CCNE1CDK2IDH1
SCHEMBL29763308 0.85 CCNT1 (0.44) CDK9CCNT1CCNE1CDK2IDH1
SCHEMBL15102262 0.85 CCNT1 (0.44) CDK9CCNT1CCNE1CDK2IDH1
SCHEMBL16392262 0.84 TNNI3K (0.46) CDK9CCNT1CCNE1CDK2SYK
SCHEMBL15102388 0.84 KCNH3 (0.55) CDK9CCNT1CCNE1CDK2IDH1
SCHEMBL15102363 0.83 KCNH3 (0.54) IDH1IDH2KCNH3POLB
SCHEMBL29561157 0.83 IDH1 (0.53) CDK9CCNT1CCNE1CDK2IDH1
SCHEMBL15102540 0.83 IDH1 (0.53) CDK9CCNT1CCNE1CDK2IDH1
SCHEMBL15102434 0.82 IDH1 (0.71) IDH1IDH2SYK
SCHEMBL29560264 0.82 IDH1 (0.71) IDH1IDH2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
CN-115536635-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-12-30 — — CN disclosed
CN-115521264-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-12-27 — — CN disclosed
US-11505538-B1 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2022-11-22 — — US disclosed
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2022-11-03 — — US disclosed
CN-114933585-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-08-23 — — CN disclosed
CN-108912066-B Therapeutically active compounds and methods of use thereof 安吉奥斯医药品有限公司 2022-06-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT CDK9 1498/4885CCNT1 2401/4885CCNE1 1760/4885
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT CDK9 1498/4885CCNT1 2401/4885CCNE1 1760/4885
US-11505538-B1 Therapeutically active compounds and their methods of use MCL1, TP53, BRDT CDK9 1498/4885CCNT1 2401/4885CCNE1 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback